Ocugen’s stock is up 14% after announcing manufacturing partner for experimental COVID-19 shot

Shares of Ocugen Inc. OCGN, -3.31% gained 14.3% in premarket trading on Tuesday after the company said it picked Jubilant HollisterStier, a privately held pharmaceutical contract manufacturer, to produce its still-investigational COVID-19 vaccine for the U.S. and Canada. The vaccine is not authorized or approved in either country at this time. Ocugen’s stock is up 239.4% so far this year, while the broader S&P 500 SPX, +0.18% has gained 13.3%.

View Article Origin Here